Indoco’s CRO AnaCipher Secures ANVISA Brazil Regulatory Approval
Indoco Remedies Ltd · Press Release · 27 Oct 2026, 9:07 pm
Indoco’s CRO AnaCipher Secures ANVISA Brazil Regulatory Approval Indoco Remedies announced that its clinical research organisation, AnaCipher, received regulatory approval from Brazil’s ANVISA for its clinical and bioanalytical facilities following an inspection conducted from 30th Mar'26 to 7th Apr'26. The approval authorizes AnaCipher to conduct Bioavailability and Bioequivalence studies and provide bioanalytical support for regulatory submissions in Brazil. This clearance strengthens AnaCipher’s international compliance profile, enabling Indoco to expand its contract research services across Latin American markets and support global pharmaceutical clients.
Original exchange filing (PDF)
More announcements from Indoco Remedies Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others · 13 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suresh G Kare · 09 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suresh G Kare · 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others · 06 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ms. Aditi M Panandikar & Ms. Madhura Suresh Kare · 04 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others · 03 Nov 2026
- Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-2026 · 29 Oct 2026
- Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026 · 27 Oct 2026
